Last reviewed · How we verify
Dronabinol in Oral Dosage Form
Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects.
Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects. Used for Cancer-related anorexia and cachexia (Phase 3 investigation), Chemotherapy-induced nausea and vomiting (potential indication).
At a glance
| Generic name | Dronabinol in Oral Dosage Form |
|---|---|
| Also known as | BX-1 |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Drug class | Cannabinoid receptor agonist |
| Target | CB1 receptor, CB2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Dronabinol (delta-9-tetrahydrocannabinol, THC) binds to and activates cannabinoid receptors in the central and peripheral nervous systems. This activation influences appetite regulation, nausea/vomiting pathways, and potentially anti-inflammatory and immunomodulatory processes. The exact mechanisms in oncology contexts may involve appetite stimulation, symptom management, and potential direct anti-tumor effects under investigation.
Approved indications
- Cancer-related anorexia and cachexia (Phase 3 investigation)
- Chemotherapy-induced nausea and vomiting (potential indication)
Common side effects
- Dizziness
- Drowsiness
- Euphoria
- Dry mouth
- Tachycardia
Key clinical trials
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- Unique Treatment of Oncology Pain in Advanced Cancer (PHASE2)
- Study of Oral Fluid Testing Approach
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Evaluation of Oral THC and CBD in Men and Women (PHASE1)
- To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease (PHASE2, PHASE3)
- PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults (EARLY_PHASE1)
- Investigation of Psychedelic Effects in Psychoactive Substances (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: